Background: Induced sputum (IS) is a noninvasive tool, which can be used to collect cellular and soluble materials from lung airways. Objective: To evaluate if IS may be a useful and safe tool for the detection of airway inflammation in patients with interstitial lung disease (ILD) in systemic sclerosis (SSc). Methods: Sixty-eight patients with SSc and ILD as well as 18 healthy individuals (controls) were selected and submitted to IS examination. In 34 of 68 patients with SSc, bronchoalveolar lavage (BAL) was also performed. Safety of IS was assessed by comparison of forced expiratory volume in the first second (FEV1), FEV1/forced vital capacity ratio and peak expiratory flow before and after the IS procedure. Cell composition in samples collected by BAL and IS was correlated, and IS total and differential cell count in SSc patients and controls were compared. Results: The total number of cells was significantly higher in IS samples of SSc patients compared to those of healthy controls. Mean percentage of neutrophils was also higher in SSc patients (41.79 ± 23.89 vs. 27.37 ± 17.90), as well as lymphocytes (17.42 ± 19.70 vs. 3.13 ± 2.28) and eosinophils (2.35 ± 4.43 vs. 0.41 ± 0.46). On the other hand, mean percentage of macrophages was higher in healthy individuals (69.10 ± 19.15 vs. 36.96 ± 20.68). In fluid recovered by BAL, the most frequent cells were macrophages (67.89% ± 17.26), while neutrophils (14.77 ± 17.18%) and lymphocytes (15.62 ± 13.46%) were less frequent and eosinophils (1.66 ± 2.08%) were rare. A similar pattern of cell composition was found in IS samples (41.15 ± 21.67% of macrophages, 39.72 ± 23.15% of neutrophils, 15.28 ± 19.46% of lymphocytes and 2.56 ± 5.03% of eosinophils). Strength of correlation between BAL and IS was significant for macrophages and neutrophils. After IS procedure was performed, improvement of FEV1 (mean value before IS was 85.09 ± 14.44 and 88.93 ± 16.40 after IS) and FEV1/forced vital capacity (mean value before IS was 98.53 ± 12.11 and 105.22 ± 10.78 after IS) was observed. Conclusion: The IS method may allow a noninvasive assessment of cell composition in airway fluid and may contribute to the better understanding of upper/medium airway inflammation in SSc. Future studies are needed to verify whether IS can replace invasive procedures for the detection and monitoring of lung inflammation in SSc.

1.
D’Angelo WA, Fries JF, Masi AT, Shulman LE: Pathologic observations in systemic sclerosis (scleroderma): a study of 58 autopsy cases and 58 matched controls. Am J Med 1969;46:428–437.
2.
Simeon CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C, et al: Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997;56:723–728.
3.
Hesselstrand R, Scheja A, Akesson A: Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682–686.
4.
Cossio M, Menon Y, Wilson W, deBoisblanc BP: Life-threatening complications of systemic sclerosis. Crit Care Clin 2002;18:819–839.
5.
Warrick JH, Balla M, Schalbel SI, et al: High resolution computer tomography in early lung disease. J Rheumatol 1991;18:1520–1528.
6.
Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al: High resolution computer tomography as predictor of lung histology in systemic sclerosis. Thorax 1992;11:465–472.
7.
Silver RM, Miller KS, Smith EA, Schabel SI: Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88:470–476.
8.
Witt C, Borgess AC, John M, et al: Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999;58:635–640.
9.
Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, Black CM, du Bois RM, Wells AU: Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007;56:2005–2012.
10.
Vatrella A, Bocchino M, Perna F, Scarpa R, Galati D, Spina S, Pelaia G, Cazzola M, Sanduzzi A: Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement Respir Med 2007;101:1383–1389.
11.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–205.
12.
Muller NL, Staples CA, Miller RR, Vedal S, Thurlbeck WM, Ostrow DN: Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radiology 1987;165:731–734.
13.
Wells AU, Rubens MB, du Bois RM, Hansell DM: Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol 1993;161:1159–1165.
14.
Miller MR, Hankinson J, Brusasco V, et al: Standardisation of spirometry. Eur Respir J 2005;26:319–338.
15.
Wanger J, Clausen JL, Coates A, et al: Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511–522.
16.
Macintyre N, Crapo RO, Viegi G, et al: Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–735.
17.
Pizzichini E, Pizzichini MMM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE: Indices of airway inflammation in induced sputum: reproducibility and validity of cell fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308–317.
18.
Spanevello A, Migliori GB, Sharara AM, Ballardin L, Bridge P, Pisati P, Neri M, Ind PW: Induced sputum to assess airway inflammation: a study of reproducibility. Clin Exp Allergy 1997;27:1138–1144.
19.
In’t Veen JCCM, De Gouw HWFM, Smits HH, Sont JK, Hiemstra PS, Sterk PJ, Bel EH: Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J 1996;9:2441–2447.
20.
Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghè B, Spanevello A: Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583–585.
21.
Spanevello A, Beghè B, Bianchi A, Migliori GB, Ambrosetti M, Neri M, Ind PW: Comparison of two methods of processing induced sputum: selected versus entire sputum. Am J Respir Crit Care Med 1988;157:665–668.
22.
Brightling C: Clinical application of induced sputum. Chest 2006;129:1344–1348.
23.
Fireman E, Lerman Y: Induced sputum in interstitial lung diseases. Curr Opin Pulm Med 2006;12:318–322.
24.
Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, et al: Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med 2002;162:1172–1174.
25.
Belda J, Leigh R, Parameswaran K, O’Byrne PM, Sears MR, Hargreave FE: Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000;161:475–478.
26.
Stanescu D, Sanna A, Veriter C, et al: Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267–271.
27.
D’Ippolito R, Foresi A, Chetta A, Casalini A, Castagnaro A, Leone C, Olivieri D: Induced sputum in patients with newly diagnosed sarcoidosis. Chest 1999;115:1611–1615.
28.
Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, König G, Fruhmann G: Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154:400–406.
29.
Ettensohn DB, Jankowski MJ, Redondo AA, Duncan PG: Bronchoalveolar lavage in the normal volunteer subject. 2. Safety and results of repeated BAL, and use in the assessment of intrasubject variability. Chest 1988;94:281–285.
30.
Fireman E, Topilsky I, Greif J, Lerman Y, Schwarz Y, Man A, Topilsky M: Induced sputum compared to bronchoalveloar lavage for evaluating patients with sarcoidosis and nongranulomatous interstitial lung disease. Respir Med 1999;93:827–834.
31.
Fireman E, Grief J, Schwarz Y: Assessment of hazardous dust exposure by BAL and induced sputum. Chest 1999;115:1720–1728.
32.
Gravelyn TR, Pan PM, Eschenbacher WL: Mediator release in an isolated airway segment in subjects with asthma. Am Rev Respir Dis 1988;137:641–646.
33.
Makker HK, Holgate ST: The contribution of neurogenic reflexes to hypertonic saline induced bronchoconstriction in asthma. J Allergy Clin Immunol 1993;92:82–88.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.